{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:20:13Z","timestamp":1793064013115,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>QuANTUM-First was a randomized trial that demonstrated that the addition of quizartinib, a potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, to induction and consolidation chemotherapy, followed by monotherapy maintenance, improved the survival for patients with newly diagnosed FLT3\u2013internal tandem duplication (FLT3-ITD)\u2013mutated acute myeloid leukemia. We conducted a post hoc analysis of the trial data focusing on measurable residual disease (MRD) as assayed using an amplicon-based next-generation sequencing assay, and on the impact of molecular biomarkers such as FLT3-ITD insertion length and comutations. This is, to our knowledge, the first prospective, randomized trial of an FLT3 inhibitor in newly diagnosed patients in which FLT3-ITD MRD data were collected throughout therapy. We established that quizartinib induces deeper remissions with respect to FLT3-ITD MRD vs placebo, and that the amount of MRD at the completion of induction correlates with relapse and survival. We found that longer FLT3-ITD insertion mutations correlated with worse outcome, quizartinib was beneficial irrespective of insertion mutation length, and the FLT3-ITD MRD assay was more sensitive when bone marrow was used vs peripheral blood. Regardless of the presence of NPM1 (nucleophosmin 1) comutation, quizartinib increased the rates of MRD negativity at the end of induction vs placebo. Finally, comparison of the FLT3-ITD mutation length between the polymerase chain reaction (PCR) with capillary electrophoresis assay obtained at screening and the PCR next-generation sequencing MRD assay performed at the end of induction showed a 96.2% concordance with the exact ITD length. This trial was registered at www.clinicaltrials.gov as #NCT02668653.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016444","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:20:32Z","timestamp":1759782032000},"page":"917-928","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["<i>FLT3<\/i>\n                    -ITD measurable residual disease from the QuANTUM-First trial"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark J.","family":"Levis","sequence":"first","affiliation":[{"name":"1Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[{"name":"2Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"3Hematology Department, La Fe University and Polytechnic Hospital, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Vrhovac","sequence":"additional","affiliation":[{"name":"5Division of Hematology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-4310","authenticated-orcid":false,"given":"El\u017cbieta","family":"Patkowska","sequence":"additional","affiliation":[{"name":"6Institute of Hematology and Blood Transfusion, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"\u017d\u00e1k","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"8Division of Hematology-Oncology, Chang Gung Medical Foundation, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E.","family":"Connolly Rohrbach","sequence":"additional","affiliation":[{"name":"9Daiichi Sankyo, Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken C. N.","family":"Chang","sequence":"additional","affiliation":[{"name":"9Daiichi Sankyo, Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"9Daiichi Sankyo, Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Mostafa Kamel","sequence":"additional","affiliation":[{"name":"9Daiichi Sankyo, Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Imadalou","sequence":"additional","affiliation":[{"name":"9Daiichi Sankyo, Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Lesegretain","sequence":"additional","affiliation":[{"name":"9Daiichi Sankyo, Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Augusta University Medical Center, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Saint Louis Hospital, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Amadori","sequence":"additional","affiliation":[{"name":"13Department of Biomedicine and Prevention, Tor Vergata Polyclinic Hospital Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"14Institute of Hematology and Blood Diseases Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-2059","authenticated-orcid":false,"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[{"name":"15National Center of Tumor Diseases Trial Center, German Cancer Research Center, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"12","key":"2026021015515541400_bib1","first-page":"1911","article-title":"Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"issue":"6","key":"2026021015515541400_bib2","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2026021015515541400_bib3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"issue":"9","key":"2026021015515541400_bib4","first-page":"3074","article-title":"Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia","volume":"93","author":"Kiyoi","year":"1999","journal-title":"Blood"},{"issue":"13","key":"2026021015515541400_bib5","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2026021015515541400_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2026021015515541400_bib7","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"issue":"suppl 15","key":"2026021015515541400_bib8","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1200\/jco.2009.27.15_suppl.7065","article-title":"Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias","volume":"27","author":"Pratz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026021015515541400_bib9","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026021015515541400_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"2026021015515541400_bib11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"10388","key":"2026021015515541400_bib12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2026021015515541400_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026021015515541400_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026021015515541400_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.13110","article-title":"Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia","volume":"94","author":"Hess","year":"2009","journal-title":"Haematologica"},{"issue":"22","key":"2026021015515541400_bib16","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026021015515541400_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","article-title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","volume":"36","author":"R\u00fccker","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2026021015515541400_bib18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026021015515541400_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.2019002180","article-title":"FLT3 inhibitors added to induction therapy induce deeper remissions","volume":"135","author":"Levis","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2026021015515541400_bib20","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3324\/haematol.2022.281218","article-title":"Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis","volume":"107","author":"Polak","year":"2022","journal-title":"Haematologica"},{"issue":"26","key":"2026021015515541400_bib21","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026021015515541400_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"2026021015515541400_bib23","doi-asserted-by":"crossref","first-page":"22812","DOI":"10.18632\/oncotarget.4333","article-title":"Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia","volume":"6","author":"Bibault","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"2026021015515541400_bib24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2026021015515541400_bib25","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"15","key":"2026021015515541400_bib26","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021015515541400_bib27","unstructured":"Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment. Accessed 9 October 2025. https:\/\/www.fda.gov\/media\/134605\/download."},{"issue":"19","key":"2026021015515541400_bib28","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026021015515541400_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"2026021015515541400_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7","key":"2026021015515541400_bib31","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","article-title":"Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study","volume":"36","author":"White","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2026021015515541400_bib32","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","article-title":"Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia","volume":"107","author":"Stirewalt","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2026021015515541400_bib33","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","article-title":"Impact of FLT3-ITD length on prognosis of acute myeloid leukemia","volume":"104","author":"Liu","year":"2019","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/917\/2503349\/blooda_adv-2025-016444-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/917\/2503349\/blooda_adv-2025-016444-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:52:07Z","timestamp":1770756727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/917\/547586\/FLT3-ITD-measurable-residual-disease-from-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016444","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,2,10]]}}}